Assay News and Research

RSS

New in vitro 12-cell line panel assay predicts anti-cancer drug activity

Southern Research Institute today announced a new service offering - a novel in vitro 12-cell line panel assay designed to predict drug activity and improve the success rate of drugs tested in xenograft models.

21 May 2014

The future of high throughput screening: an interview with Mark Wigglesworth, Director High Throughput Screening, AstraZeneca

Quoting Mike Snowden (VP & Head of Discovery Sciences, AstraZeneca), “it’s where biology meets chemistry”. It’s where for the first time a target protein can be probed for novel molecules that modulate its function, of course we want to do this to prove a hypothesis that these proteins are drug targets with the potential to deliver innovative medicines.

20 May 2014

Sanofi presents Phase II trial results for investigational vaccine for prevention of CDI

Sanofi Pasteur, the vaccines division of Sanofi, presented Phase II (H-030-012) trial results for an investigational vaccine for the prevention of Clostridium difficile infection at the 114th General Meeting of the American Society for Microbiology.

20 May 2014

Urine test can indicate presence of venous thromboembolism in patients at risks for clots

A new study by researchers from California and Canada indicates a simple urine test can indicate the presence of venous thromboembolism, a blood clot that has broken free from its point of origin and which travels through the bloodstream, eventually lodging in a vein.

19 May 2014

Corgenix announces that Randox received CE Mark notification for TxBCardio Assay

Corgenix Medical Corporation announced in collaboration with Randox Laboratories that Randox has been granted CE Mark notification for its TxBCardio™ Assay.

From Randox Laboratories Ltd. 15 May 2014

Introduction to Solid State ChIP technology

A new instructional video from Porvair Sciences explains exactly how to conduct a ChIP assay for epigenetic research starting from a confluent monolayer of human cells.

From Chromatrap® - Porvair Sciences Ltd 14 May 2014

Luminex announces group B strep as fifth assay planned for launch menu of ARIES

Luminex Corporation today announced that Group B Streptococcus (group B strep, GBS) is the fifth assay planned for the launch menu of its new sample-to-answer system, ARIES™.

From Luminex 12 May 2014

Pfizer reports positive results from rLP2086 Phase 2 study for invasive meningococcal disease

Pfizer Inc. announced today the results from two Phase 2 studies of bivalent rLP2086, Pfizer's recombinant vaccine candidate, currently under development for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B in 10 to 25 year olds.

12 May 2014

Cellectricon, Neusentis to host webinar on phenotypic screening approaches in pain research

Cellectricon, a leading provider of advanced cell-based screening technologies and services, will co-host a webinar with Neusentis, describing the use of native cells to develop an assay with improved physiological relevance over traditional approaches in pain drug discovery research.

From Cellectricon 8 May 2014

Leica and Affymetrix launch fully automated RNA in situ hybridization assays

Affymetrix, Inc. (NASDAQ:AFFX) and Leica Biosystems announce the launch of Affymetrix' fully automated RNA in situ hybridization assays ViewRNATM eZ Assays on the Leica BOND RX staining platform.

8 May 2014

FDA-cleared BD MAX Enteric Bacterial Panel now available to detect bacterial pathogens

BD Diagnostics, a segment of leading global medical technology company BD (Becton, Dickinson and Company), announced today the availability of the FDA-cleared BD MAX Enteric Bacterial Panel for use on the BD MAX System.

From BD (Becton, Dickinson and Company) 7 May 2014

Molecular subtyping provides insights into how to treat breast cancer

New evidence showing that the MammaPrint® and BluePrint® tests provide insights into how to treat breast cancer was presented at the annual conference of the American Society of Breast Surgeons (ASBrS).

7 May 2014

NanoString receives license from Health Canada to market Prosigna Breast Cancer Prognostic Gene Signature Assay

NanoString Technologies, Inc., a provider of life science tools for translational research and molecular diagnostic products, today announced that it has received a Class III Medical Device License from Health Canada, clearing the company to market its Prosigna Breast Cancer Prognostic Gene Signature Assay for assessing a woman's 10-year risk of distant recurrence and accurately identifying the intrinsic biologic subtype of the tumor.

From NanoString Technologies 7 May 2014

Isis Pharmaceuticals reports pro forma net operating loss of $22.6 million for Q1 2014

Isis Pharmaceuticals, Inc. today reported a pro forma net operating loss (NOL) of $22.6 million for the three months ended March 31, 2014 compared to pro forma operating income of $4.5 million for the same period in 2013.

6 May 2014

UCB announces results from PRECiSE clinical trial of Cimzia in patients with Crohn's disease

UCB announced today results from the PRECiSE 3 7-year open label extension clinical trial of Cimzia (certolizumab pegol), the longest continuous trial of an anti-TNF therapy evaluating long-term safety in Crohn's disease.

6 May 2014

Novogen partners with Genea Biocells to accelerate testing for neurodegenerative diseases

Novogen Limited, an oncology drug development company, today announced a collaboration with Australian company, Genea Biocells, to accelerate testing of their super-benzopyran (SBP) drugs for degenerative diseases of the nervous system and muscles.

5 May 2014

Enrichment of highly abundant epigenetic marks from endometrial stromal cells

Chromatrap®, the novel solid-based matrix for chromatin immunoprecipitation (ChIP) assays, available from Porvair Sciences, has been successfully used to isolate high quality chromatin from difficult biopsy material.

From Chromatrap® - Porvair Sciences Ltd 30 Apr 2014

InDevR, Applied Microarrays partner to offer complete system solution for multiplexed assays

InDevR Inc., a Boulder-based biotechnology company, and Applied Microarrays, Inc., a Tempe-based contract microarray manufacturer have partnered to deliver a complete system solution for multiplexed assays. The platform includes custom protein and DNA arrays, reagents and protocols, a fluorescent scanner for slides or plates (Vidia) and a colorimetric scanner for lower throughput applications (ampliPHOX).

30 Apr 2014

Illumina launches VeriSeq PGS for preimplantation genetic screening of embryos

Illumina, Inc. today announced the launch of VeriSeq PGS, a next-generation sequencing solution developed for preimplantation genetic screening of embryos using Illumina's NextSeq 500 and MiSeq® sequencing systems.

From Illumina, Inc. 29 Apr 2014

Mayo Clinic launches new gene panel cancer test to help tailor chemotherapy

Mayo Clinic announces the launch of CANCP, a new gene panel cancer test to help tailor chemotherapy to the individual patient based on the unique genomic signature of the patient's tumor.

29 Apr 2014